Research programme: analgesic therapeutics - Vernalis

Drug Profile

Research programme: analgesic therapeutics - Vernalis

Alternative Names: 1X 2000; 1X 3000; Analgesic therapeutics research programme - Vernalis; IX 4000

Latest Information Update: 16 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vernalis
  • Class Proteins
  • Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain; Urinary incontinence

Most Recent Events

  • 26 Jul 2005 Ionix Pharmaceuticals has been acquired and merged into Vernalis
  • 29 Mar 2005 Preclinical trials in Urinary incontinence in United Kingdom (unspecified route)
  • 25 Feb 2002 Preclinical trials in Pain in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top